INCYTE CORP reported revenue of $1.67B for the period ended 2026-06-30, +37.7% year on year. Net income was $0.59B, a 35.0% net margin on a 93.7% gross margin. The largest revenue line is Net sales at 89% of the total. Free cash flow for the period was $0.50B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $1.67B | +37.7% |
| Gross profit | $1.57B | — |
| Operating income | $0.70B | — |
| Net income | $0.59B | +44.6% |
| Gross margin | 93.7% | Net margin 35.0% |
| Revenue Q/Q | +31.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| Net sales | $1.49B | 88.9% |
| Product royalty revenues | $0.17B | 10.4% |
| Milestone and contract revenues | $0.01B | 0.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.10B | 6.3% |
| R&D | $0.52B | 30.9% |
| SG&A | $0.35B | 21.0% |
| Tax & other | $0.11B | 6.9% |
| Item | Amount |
|---|---|
| Operating cash flow | $0.51B |
| Capital expenditure | $0.01B |
| Free cash flow | $0.50B |
| Cash conversion (OCF / net income) | 87% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
IR ・ PODD ・ INTC ・ IBKR ・ ICE ・ IFF ・ IP ・ INTU ・ ISRG ・ IVZ ・ INVH ・ IQV
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies